The Ozempic supply situation in Australia has been a source of ongoing concern for several years. What began as intermittent shortages has become a persistent challenge affecting Australians prescribed semaglutide for type 2 diabetes. Here’s what we know about the current state of affairs and what it means for the broader research landscape.
The Shortage: Where Things Stand
Semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management) has been listed on the TGA’s Medicine Shortages Database for extended periods since late 2022. The shortage is driven by global demand that has consistently outpaced manufacturing capacity.
Key facts about the current situation:
- Global demand surge: The popularity of GLP-1 receptor agonists has grown exponentially worldwide, driven by both on-label prescribing and off-label use.
- Supply constraints: Manufacturer Eli Lilly and Novo Nordisk have invested billions in expanding production capacity, but these facilities take years to come online.
- TGA shortage listings: The TGA has maintained shortage notifications for various semaglutide formulations, with different pen strengths affected at different times.
- Priority access: Australian health authorities have periodically issued guidance prioritising supply for existing type 2 diabetes patients over new initiations.
Compounding Pharmacy Context
During shortages, compounding pharmacies have occasionally been permitted to prepare semaglutide preparations under specific regulatory frameworks. This is a nuanced area:
- The TGA has issued temporary provisions allowing compounding of certain shortage-listed medicines.
- Compounded preparations are not equivalent to TGA-registered products and do not undergo the same quality assurance processes.
- This area remains subject to evolving regulation, and the TGA has periodically adjusted its position on compounded GLP-1 preparations.
For researchers, the compounding context raises important questions about quality control, standardisation, and regulatory oversight that are worth understanding.
Alternative Compounds in the Research Pipeline
The supply challenges surrounding semaglutide have accelerated interest in alternative GLP-1 and incretin compounds. Several are generating significant research interest:
Tirzepatide (Mounjaro) A dual GLP-1/GIP receptor agonist now TGA-approved in Australia. While it faces its own supply constraints, tirzepatide offers a different pharmacological profile as a dual agonist.
Retatrutide (LY3437943) A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data has shown promising results in metabolic research settings. Read more about retatrutide’s mechanism →
Orforglipron An oral non-peptide GLP-1 agonist under development. The prospect of a pill-form GLP-1 compound could address supply and administration challenges associated with injectable peptides.
Survodutide A dual glucagon/GLP-1 receptor agonist in clinical development, with particular research interest in its effects on liver fat metabolism.
CagriSema A combination of semaglutide and cagrilintide (a long-acting amylin analogue) being studied in Phase 3 trials for metabolic research applications.
Community Perspective
The Australian community following GLP-1 research has responded to the shortage situation with a mix of frustration and increased scientific curiosity. Several themes have emerged:
- Research literacy: Supply challenges have motivated many community members to deepen their understanding of the broader peptide landscape rather than focusing on a single compound.
- Regulatory awareness: There’s growing interest in how the TGA framework governs these compounds and what the pipeline looks like.
- Community support: Sharing of publicly available research information has become a cornerstone of community discussion. Our Telegram community is a space where members discuss published research findings and regulatory developments.
For a broader understanding of the compounds generating research interest, visit our peptides overview.
Looking Ahead
The Ozempic shortage highlights a broader structural issue: demand for incretin-based therapies is outstripping global manufacturing capacity in the short to medium term. As new production facilities come online and alternative compounds advance through clinical development, supply pressures are expected to gradually ease.
In the meantime, the situation continues to drive valuable research interest in alternative compounds, combination therapies, and oral formulations - developments that will shape the metabolic research landscape for years to come.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.